Showing results (31-40 of 126) with videos related to

Sort By:
Pageof 13
Acta Haematologica|September 29, 2025
Real World Experience of Azacitidine + Venetoclax in Acute Myeloid Leukemia Rigorously Following Management Guidelines from Clinical TrialBochra Sedaki, Alexandre Iat, Sami Benachour, et al.
Annals of Hematology|February 9, 2025
Novel ETV6::RAPGEF6 fusion gene in chronic eosinophilic leukemia: compiling evidence on the role of IL3 overexpression in tumorigenesisMathilde Iberti, Michael Loschi, Frédérique Keslair, et al.
Oncotarget|June 26, 2014
Phenotypic and genotypic characterization of azacitidine-sensitive and resistant SKM1 myeloid cell linesThomas Cluzeau, Alix Dubois, Arnaud Jacquel, et al.
Oncoimmunology|March 7, 2022
Reprogramming monocyte-derived macrophages through caspase inhibitionPaul Chaintreuil, Lucie Laplane, Florian Esnault, et al.
Cancer Medicine|March 20, 2024
Comparison of clinical outcomes of several risk stratification tools in newly diagnosed AML patients: A real-world evidence in our current therapeutic eraAlexandre Iat, Michael Loschi, Sami Benachour, et al.
Oncotarget|May 12, 2012
BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patientsThomas Cluzeau, Guillaume Robert, Nicolas Mounier, et al.
Leukemia Research|November 8, 2017
Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidineMarie Sébert, Rami S Komrokji, Mikkael A Sekeres, et al.
Blood Advances|August 15, 2023
Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3-mutated AML: a phase 3b trialJorge Sierra, Pau Montesinos, Xavier Thomas, et al.
American Journal of Hematology|June 13, 2013
Monosomal karyotype improves IPSS-R stratification in MDS and AML patients treated with AzacitidineThomas Cluzeau, Nicolas Mounier, Jean-Michel Karsenti, et al.
European Journal of Haematology|January 29, 2020
Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatmentAnne Calleja, Seongseok Yun, Chimène Moreilhon, et al.
Pageof 13